Registered outcomes23

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

21 to 23 of 23

List	Outcome	Time frame	Description
Other	Number of participants experiencing specific therapy-related infection events	1 year after completion of therapy for last enrolled patient (up to 3.5 years after enrollment)	All enrolled participants will be eligible for this component. Descriptive statistics, such as frequency and proportion, will be summarized for breakthrough infections, antibiotic-resistant infections, febrile neutropenia episodes and adverse events. Cumulative incidence of breakthrough infection, febrile neutropenia and adverse events will also be explored, with competing risks and/or recurrent event appropriately adjusted.
Other	5-year EFS of MPAL patients	3.5 years after enrollment of the last patient	Kaplan-Meier estimates of EFS curve in patients with MPAL will be computed.
Other	5-year OS of MPAL patients	3.5 years after enrollment of the last patient	Kaplan-Meier estimates of OS curve in patients with MPAL will be computed.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03117751/registered?page=2